Kazakhstan Medical Device Technical Documentation and Risk Management: Review Focus and Filing Practice

Updated: 2026-11-12 · GRZAN Regulatory Team · Verification date 2026-10-20

1. Key takeaways

Technical documentation and risk management documentation are the main battleground of registration review in Kazakhstan: the overwhelming majority of deficiency questions originate from these two files. The technical documentation must answer what the product is, how it is manufactured, and on what basis it is safe and effective, while the risk management documentation must answer how risks are identified, controlled and verified. Both must maintain a searchable correspondence with the general safety and effectiveness requirements of Decision No. 27. The high-frequency deficiencies recorded by GRZAN concentrate on a single failure mode: the conclusions of the risk management documentation are never traced back to the verification evidence in the technical documentation. A dossier that closes that loop, item by item, removes the largest single source of review delay and signals a mature quality culture to the reviewing expert.

2. Legal basis

RegulationNumberDateProvisions
Decision of the Board of the Eurasian Economic Commission on General Requirements for the Safety and Effectiveness of Medical Devices and Requirements for Their Labeling and Operating DocumentationDecision No. 27February 12, 2016General safety and effectiveness requirements
Order of the Minister of Healthcare on approval of the Rules for National Registration, Re-registration and Changes to Registration Dossiers of Medicinal Products and Medical DevicesOrder No. ҚР ДСМ-16February 9, 2021 (Ministry of Justice registration No. 22175)Dossier document requirements
Order of the Minister of Healthcare on approval of the Rules for Expert Evaluation (Examination) of the Safety, Quality and Effectiveness of Medicinal Products and Medical DevicesOrder No. ҚР ДСМ-10January 27, 2021Verification focus of the expert review
International standard ISO 14971Risk managementcurrent versionRisk management process
International standard ISO 13485:2016Quality management systemcurrent versionDesign controls and document management

3. Expert insights

Insight one: the risk management documentation is not a risk list, it is a decision chain. A compliant risk management file must present the complete chain: risk identification, risk evaluation, risk control measures, verification of those measures, evaluation of residual risk, and the benefit-risk conclusion. What the reviewer examines is the closed nature of the chain, and above all the link on whether control measures have been verified. Listing risks and measures without supplying verification evidence is the single most frequent deficiency, and it is also the easiest to prevent before submission by auditing the file against ISO 14971 expectations. A file that can be walked end to end in one reading, with every measure pointing to a test, an inspection step or a design feature, gives the reviewer nothing to question on this axis and shortens the review measurably.

Insight two: a checklist of the general safety and effectiveness requirements is the reviewer’s roadmap. Decision No. 27 establishes the general requirements, and the reviewer will work through them requirement by requirement, locating the corresponding section of the technical documentation. The GRZAN practice is to build a three-column cross-reference table linking each requirement to the document section and the supporting evidence, and to place it at the very front of the dossier so the reviewer can navigate quickly and form a favorable first impression of dossier discipline.

Insight three: version consistency across the technical documentation matters more than thickness. When parameters or wording diverge between the technical documentation, the risk management file, the operating documentation and the label texts, a chain reaction of deficiency questions follows. Shelf life, sterilization method, storage conditions and model specifications are the fields that recur across many documents, and they are therefore the classic zones of version drift. A single reconciliation pass before submission eliminates most of these findings at negligible cost.

Insight four: software and software-containing devices need a dedicated section in the technical documentation. The algorithm description, data governance, and verification and validation activities constitute an independent block of evidence and must not be buried inside the hardware description. The Union-side classification rules were adjusted for the software category by Amendment No. 18 dated February 18, 2025, and the structure of the technical documentation must be adapted to that updated practical estimate of how software is assessed, so that classification conclusions and documentation architecture stay aligned.

Insight five: the risk management documentation is the starting point of post-market surveillance. Its conclusions carry forward into the post-market phase: the acceptability judgment on residual risk determines the focus of post-market surveillance, and the evaluation of adverse events is compared back against the same file. After certification the document is not archived and forgotten; it is a living object that must be maintained, and reviewers increasingly ask how updates will be triggered and recorded. Building the update triggers into the certified quality system, rather than into an informal understanding, keeps the file and the field data permanently aligned.

4. Practical recommendations

  1. Build a three-column cross-reference table of requirement, document section and evidence, and place it at the front of the dossier for review retrieval.
  2. Provide verification evidence for every control measure in the risk management documentation; never list measures without evidence.
  3. Run a cross-document consistency check on recurring parameters such as shelf life, sterilization method, storage conditions and model specifications.
  4. Give software and software-containing devices a dedicated section in the technical documentation covering algorithms, data, and verification and validation.
  5. After certification, place the risk management documentation on a periodic maintenance cycle, updated in line with post-market surveillance data.

5. Verification checklist

  • □ The risk management documentation presents a complete decision chain, with verification evidence attached to every control measure
  • □ The three-column cross-reference table of requirement, document section and evidence is placed at the front of the dossier
  • □ The cross-document parameter consistency check is complete (shelf life, sterilization, storage, models)
  • □ The software portion forms a dedicated section within the technical documentation
  • □ The acceptability conclusion on residual risk is explicit and corresponds to the post-market surveillance focus
  • □ Document version control rules are established and maintained after certification

GRZAN provides registration support in Kazakhstan for manufacturers, importers and authorized representatives, covering technical documentation, risk management files, expert review liaison and post-approval maintenance. For assistance, contact info@grzanglobal.com.

Regulatory information verified as of October 29, 2026.

Disclaimer

Prepared by GRZAN from publicly available regulation. It is provided for general information only and does not constitute legal advice. Legislation and official fees are subject to change by the competent authority.

About GRZAN

GRZAN (Global Regulatory Zone Access Navigator) — the global market-access navigator for medical devices and IVDs.

GRZAN is a specialist consultancy for medical device and IVD market access, providing end-to-end regulatory solutions across the product lifecycle and making international market entry simpler and faster.

Key figures. More than 25 wholly owned subsidiaries worldwide covering 50+ countries and regions; chosen by 100+ listed and leading Chinese device manufacturers, with 4,000+ successful cases; 12+ years in the sector and 200+ regulatory training sessions and seminars delivered.

What we do. Global market access: multi-country registration programmes, technical documentation, regulatory advice. Clinical evidence: clinical evaluation reports (CER), usability studies, overseas clinical investigations. Quality systems: ISO 13485, MDSAP, FDA QMSR and BGMP implementation and audit readiness. Authorised representative and licence-holder services across Southeast Asia, Latin America, the Middle East, Africa, Europe and North America.

Why GRZAN. A real operating entity, with the certificate held by the manufacturer: our direct overseas subsidiaries act as the compliant local holder, so the regulatory relationship stays clear and you keep control rather than being tied to a distributor. Direct access to the team: no time-zone gap, no language barrier, no cultural gap. Review points anticipated: we know what FDA 510(k), EU MDR, Southeast Asian, Latin American and Middle Eastern reviewers look for, which shortens timelines and reduces deficiency letters. Pathway planning: pre-decision analysis and risk assessment before you commit.

Every engagement rests on three commitments: efficiency through pre-submission review, certainty through a clear pathway, and stability through a licence-holder that stays in place.

Take your devices global with GRZAN

We work with manufacturers worldwide to open new markets with a clear regulatory pathway.

Contact us
WhatsApp
QR Code
WhatsApp QR Code
Scan to chat on WhatsApp
Phone
Call
Office Mon-Fri 9:00-18:00
0755-88659477
Mobile 24/7 Service
+86 15816864648
Email
Mail